AAPL281.62-2.17 (-0.76%) ▼|ABBV253.74+0.39 (+0.15%) ▲|ABT93.48-0.64 (-0.68%) ▼|ACN125.21-3.77 (-2.92%) ▼|ADBE205.52+2.79 (+1.38%) ▲|AMAT697.81+70.97 (+11.32%) ▲|AMD537.18+15.60 (+2.99%) ▲|AMGN359.53+1.20 (+0.33%) ▲|AMT169.07-6.52 (-3.71%) ▼|AMZN240.98+8.29 (+3.56%) ▲|AVGO375.57+10.55 (+2.89%) ▲|AXP340.57+0.21 (+0.06%) ▲|BA214.78-2.48 (-1.14%) ▼|BAC58.14+0.26 (+0.44%) ▲|BKNG184.63+3.17 (+1.74%) ▲|BLK949.75-14.96 (-1.55%) ▼|BMY57.68+0.16 (+0.27%) ▲|BNY144.77+1.21 (+0.84%) ▲|BRK-B497.68-0.98 (-0.20%) ▼|C142.97+1.21 (+0.85%) ▲|CAT1,019.18+21.71 (+2.18%) ▲|CL91.52-0.55 (-0.60%) ▼|CMCSA24.78+1.61 (+6.93%) ▲|COF202.53-1.47 (-0.72%) ▼|COP104.59-1.37 (-1.29%) ▼|COST954.12+1.58 (+0.17%) ▲|CRM159.10+0.73 (+0.46%) ▲|CSCO117.49+3.72 (+3.27%) ▲|CVS104.22-0.12 (-0.12%) ▼|CVX168.87-2.19 (-1.28%) ▼|DE614.43+1.19 (+0.19%) ▲|DHR193.13-3.07 (-1.56%) ▼|DIS99.10+0.31 (+0.31%) ▲|DUK128.02-0.39 (-0.30%) ▼|EMR142.25-1.24 (-0.86%) ▼|FDX323.15+4.62 (+1.45%) ▲|GD350.29+3.58 (+1.03%) ▲|GE373.97+4.97 (+1.35%) ▲|GEV1,085.90+40.73 (+3.90%) ▲|GILD126.13-1.75 (-1.37%) ▼|GM77.57-0.53 (-0.68%) ▼|GOOG349.67+14.98 (+4.47%) ▲|GOOGL351.62+14.23 (+4.22%) ▲|GS1,022.97+3.36 (+0.33%) ▲|HD347.86-1.00 (-0.29%) ▼|HON237.93-5.49 (-2.25%) ▼|IBM274.26+2.63 (+0.97%) ▲|INTC125.84-2.48 (-1.93%) ▼|INTU268.35+0.63 (+0.23%) ▲|ISRG405.81+1.54 (+0.38%) ▲|JNJ255.38+0.72 (+0.28%) ▲|JPM331.47+2.42 (+0.74%) ▲|KO82.91+0.28 (+0.34%) ▲|LIN508.81-10.81 (-2.08%) ▼|LLY1,210.75+2.63 (+0.22%) ▲|LMT504.69-2.71 (-0.53%) ▼|LOW220.25-2.23 (-1.00%) ▼|LRCX409.96+30.87 (+8.14%) ▲|MA510.18+11.16 (+2.24%) ▲|MCD266.65-3.11 (-1.15%) ▼|MDLZ59.88-0.91 (-1.50%) ▼|MDT81.46+0.48 (+0.59%) ▲|META564.60+14.35 (+2.61%) ▲|MMM163.85-0.17 (-0.10%) ▼|MO73.38-0.41 (-0.56%) ▼|MRK128.99+0.33 (+0.25%) ▲|MS213.25+1.22 (+0.58%) ▲|MSFT371.38-1.59 (-0.43%) ▼|MU1,093.91-38.42 (-3.39%) ▼|NEE87.54-1.03 (-1.16%) ▼|NFLX75.19+1.38 (+1.87%) ▲|NKE41.23+0.48 (+1.17%) ▲|NOW100.79+2.45 (+2.49%) ▲|NVDA193.91+1.38 (+0.72%) ▲|ORCL149.04+0.51 (+0.34%) ▲|PEP139.07-2.32 (-1.64%) ▼|PFE24.17-0.12 (-0.49%) ▼|PG147.47-1.55 (-1.04%) ▼|PLTR115.77+2.84 (+2.51%) ▲|PM180.45-0.32 (-0.18%) ▼|QCOM191.79+2.40 (+1.27%) ▲|RTX188.03+0.04 (+0.02%) ▲|SBUX103.23-1.37 (-1.31%) ▼|SCHW90.99+0.32 (+0.35%) ▲|SO96.86-0.31 (-0.31%) ▼|SPG225.53-1.36 (-0.60%) ▼|T21.52-1.21 (-5.30%) ▼|TMO503.37-9.67 (-1.88%) ▼|TMUS174.00-8.68 (-4.75%) ▼|TSLA399.97+20.26 (+5.34%) ▲|TXN286.92+1.50 (+0.52%) ▲|UBER75.58-0.62 (-0.81%) ▼|UNH418.00-9.89 (-2.31%) ▼|UNP271.49+3.14 (+1.17%) ▲|UPS107.24-0.91 (-0.84%) ▼|USB61.48+0.57 (+0.93%) ▲|V341.64+5.41 (+1.61%) ▲|VZ43.30-3.25 (-6.97%) ▼|WFC84.27+0.41 (+0.49%) ▲|WMT114.68-1.01 (-0.87%) ▼|XOM135.76-0.78 (-0.57%) ▼|AAPL281.62-2.17 (-0.76%) ▼|ABBV253.74+0.39 (+0.15%) ▲|ABT93.48-0.64 (-0.68%) ▼|ACN125.21-3.77 (-2.92%) ▼|ADBE205.52+2.79 (+1.38%) ▲|AMAT697.81+70.97 (+11.32%) ▲|AMD537.18+15.60 (+2.99%) ▲|AMGN359.53+1.20 (+0.33%) ▲|AMT169.07-6.52 (-3.71%) ▼|AMZN240.98+8.29 (+3.56%) ▲|AVGO375.57+10.55 (+2.89%) ▲|AXP340.57+0.21 (+0.06%) ▲|BA214.78-2.48 (-1.14%) ▼|BAC58.14+0.26 (+0.44%) ▲|BKNG184.63+3.17 (+1.74%) ▲|BLK949.75-14.96 (-1.55%) ▼|BMY57.68+0.16 (+0.27%) ▲|BNY144.77+1.21 (+0.84%) ▲|BRK-B497.68-0.98 (-0.20%) ▼|C142.97+1.21 (+0.85%) ▲|CAT1,019.18+21.71 (+2.18%) ▲|CL91.52-0.55 (-0.60%) ▼|CMCSA24.78+1.61 (+6.93%) ▲|COF202.53-1.47 (-0.72%) ▼|COP104.59-1.37 (-1.29%) ▼|COST954.12+1.58 (+0.17%) ▲|CRM159.10+0.73 (+0.46%) ▲|CSCO117.49+3.72 (+3.27%) ▲|CVS104.22-0.12 (-0.12%) ▼|CVX168.87-2.19 (-1.28%) ▼|DE614.43+1.19 (+0.19%) ▲|DHR193.13-3.07 (-1.56%) ▼|DIS99.10+0.31 (+0.31%) ▲|DUK128.02-0.39 (-0.30%) ▼|EMR142.25-1.24 (-0.86%) ▼|FDX323.15+4.62 (+1.45%) ▲|GD350.29+3.58 (+1.03%) ▲|GE373.97+4.97 (+1.35%) ▲|GEV1,085.90+40.73 (+3.90%) ▲|GILD126.13-1.75 (-1.37%) ▼|GM77.57-0.53 (-0.68%) ▼|GOOG349.67+14.98 (+4.47%) ▲|GOOGL351.62+14.23 (+4.22%) ▲|GS1,022.97+3.36 (+0.33%) ▲|HD347.86-1.00 (-0.29%) ▼|HON237.93-5.49 (-2.25%) ▼|IBM274.26+2.63 (+0.97%) ▲|INTC125.84-2.48 (-1.93%) ▼|INTU268.35+0.63 (+0.23%) ▲|ISRG405.81+1.54 (+0.38%) ▲|JNJ255.38+0.72 (+0.28%) ▲|JPM331.47+2.42 (+0.74%) ▲|KO82.91+0.28 (+0.34%) ▲|LIN508.81-10.81 (-2.08%) ▼|LLY1,210.75+2.63 (+0.22%) ▲|LMT504.69-2.71 (-0.53%) ▼|LOW220.25-2.23 (-1.00%) ▼|LRCX409.96+30.87 (+8.14%) ▲|MA510.18+11.16 (+2.24%) ▲|MCD266.65-3.11 (-1.15%) ▼|MDLZ59.88-0.91 (-1.50%) ▼|MDT81.46+0.48 (+0.59%) ▲|META564.60+14.35 (+2.61%) ▲|MMM163.85-0.17 (-0.10%) ▼|MO73.38-0.41 (-0.56%) ▼|MRK128.99+0.33 (+0.25%) ▲|MS213.25+1.22 (+0.58%) ▲|MSFT371.38-1.59 (-0.43%) ▼|MU1,093.91-38.42 (-3.39%) ▼|NEE87.54-1.03 (-1.16%) ▼|NFLX75.19+1.38 (+1.87%) ▲|NKE41.23+0.48 (+1.17%) ▲|NOW100.79+2.45 (+2.49%) ▲|NVDA193.91+1.38 (+0.72%) ▲|ORCL149.04+0.51 (+0.34%) ▲|PEP139.07-2.32 (-1.64%) ▼|PFE24.17-0.12 (-0.49%) ▼|PG147.47-1.55 (-1.04%) ▼|PLTR115.77+2.84 (+2.51%) ▲|PM180.45-0.32 (-0.18%) ▼|QCOM191.79+2.40 (+1.27%) ▲|RTX188.03+0.04 (+0.02%) ▲|SBUX103.23-1.37 (-1.31%) ▼|SCHW90.99+0.32 (+0.35%) ▲|SO96.86-0.31 (-0.31%) ▼|SPG225.53-1.36 (-0.60%) ▼|T21.52-1.21 (-5.30%) ▼|TMO503.37-9.67 (-1.88%) ▼|TMUS174.00-8.68 (-4.75%) ▼|TSLA399.97+20.26 (+5.34%) ▲|TXN286.92+1.50 (+0.52%) ▲|UBER75.58-0.62 (-0.81%) ▼|UNH418.00-9.89 (-2.31%) ▼|UNP271.49+3.14 (+1.17%) ▲|UPS107.24-0.91 (-0.84%) ▼|USB61.48+0.57 (+0.93%) ▲|V341.64+5.41 (+1.61%) ▲|VZ43.30-3.25 (-6.97%) ▼|WFC84.27+0.41 (+0.49%) ▲|WMT114.68-1.01 (-0.87%) ▼|XOM135.76-0.78 (-0.57%) ▼|
30.5 C
New York
Monday, June 29, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients 
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients

LUNGevity Foundation Joins 2025 LungXperience Tour to Promote Lung Health and Early Detection Across the U.S.

Organization to Participate in 12 National Events as Part of Innovative Health Education Initiative WASHINGTON, July 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading...

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.

SMP Digital Signage Player by CAYIN Technology Sets New Standards for Multi-Sector Smart Display Solutions

TAIPEI, July 24, 2025 /PRNewswire/ -- As digital transformation deepens across industries, enterprises increasingly demand visualization and system integration of information. CAYIN Technology announces SMP...

PFPFA Malaysia Officially Launched, Marking Next Chapter in SingWealth Holdings’ Regional Growth

With the launch of PFPFA (Malaysia), SingWealth Holdings deepens its regional presence and strengthens its commitment to delivering trusted, client-centric financial advisory solutions across...

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

Local Plastic Surgeon in Paramus New Jersey, Dr. Andrew Nouri Educates Patients on Insurance Coverage for Medically Necessary Breast Reduction

Paramus, NJ, July 23, 2025 (GLOBE NEWSWIRE) -- For many women, large breasts are not just a cosmetic concern, they’re a medical one. Chronic back, neck, and shoulder pain, rashes under the breasts, painful grooves from bra straps, posture problems, and even emotional distress are just some of the symptoms that can come with disproportionately large breasts.

Happy Docs Make Happy Patients

AI technology boosts face-to-face time with patients, earns Mercy national recognition for physician satisfaction ST. LOUIS, July 23, 2025 /PRNewswire/ -- Mercy's strategic and carefully planned...

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day.

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers